Prescription-drug policy: Remove obstacles keeping alternatives from reaching the market

We’ve focused in the first two posts of this three-part series addressing prescription-drug policy (here and here) on proposals in the United States Senate which offer solutions in search of problems, harm competition and allow brand-name drug companies to continue keep life-saving generics off the market for longer periods of time – all  with costly…